✉news BusinessFinance first seen 1 d ago, last 1 d ago, peak #30
CSL and Alentis Sign $1.6 Billion Rare Disease Drug Deal
Original: CSL, Alentis Partner on $1.6B Rare Disease Drug Deal | Finance News
Australian biotech giant CSL and Swiss clinical-stage company Alentis Therapeutics have struck a partnership worth up to $1.6 billion to develop a treatment for a rare disease. Under the deal, CSL will pay upfront and milestone-based fees to gain rights to Alentis's drug candidate, adding to growing industry interest in niche rare-disease therapies.
Why now: The size of the deal and continued biotech interest in rare disease treatments are drawing attention from investors and industry watchers.
Evidence
- CSL, Alentis Partner on $1.6B Rare Disease Drug Deal | Finance News · Global Banking & Finance Review
API: https://socialmediatrends-api.osmike.com/v1/trends/1042807